Top

Current Oncology Reports

Published in:

01-05-2020 | Coronavirus | Hot Topic

COVID-19 and Cancer: a Comprehensive Review

Authors: Rohit Gosain, Yara Abdou, Abhay Singh, Navpreet Rana, Igor Puzanov, Marc S. Ernstoff

Published in: Current Oncology Reports | Issue 5/2020

Abstract

Purpose of Review

The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged to be the biggest global health threat worldwide, which has now infected over 1.7 million people and claimed more than 100,000 lives around the world. Under these unprecedented circumstances, there are no well-established guidelines for cancer patients.

Recent Findings

The risk for serious disease and death in COVID-19 cases increases with advancing age and presence of comorbid health conditions. Since the emergence of the first case in Wuhan, China, in December 2019, tremendous research efforts have been underway to understand the mechanisms of infectivity and transmissibility of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a fatal virus responsible for abysmal survival outcomes. To minimize the mortality rate, it becomes prudent to identify symptoms promptly and employ treatments appropriately. Even though no cure has been established, multiple clinical trials are underway to determine the most optimal strategy. Managing cancer patients under these circumstances is rather challenging, given their vulnerable status and the aggressive nature of their underlying disease.

Summary

In this comprehensive review, we discuss the impact of COVID-19 on health and the immune system of those affected, reviewing the latest treatment approaches and ongoing clinical trials. Additionally, we discuss challenges faced while treating cancer patients and propose potential approaches to manage this vulnerable population during this pandemic.

Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med. 2020;27.

Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J. Med. Virol. 2020.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94.

COVID-19 Coronavirus pandemic. [cited 2020 Apr 11]; available from: https://www.worldometers.info/coronavirus/

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.PubMedPubMedCentralCrossRef

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020.

Chavez S, Long B, Koyfman A, Liang SY. Coronavirus disease (COVID-19): a primer for emergency physicians. Am J Emerg Med. 2020.

World Health Organization. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. WHO 2020

• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; Highlights initial stages of COVID-19 was managed in China, and further management steps were utilized globally.

10.

• Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020; Highlights briefly important aspects of cancer care within the United States.

11.

Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966.

12.

Velavan TP, Meyer CG. The COVID-19 epidemic. Tropical Med. Int. Health. 2020.

13.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). 2020.

14.

• Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; This was the first study to evaluate cancer patients being at a higher risk of serious illnesses from COVID-19, and rather extra precaution is very much advised for this patient population.

15.

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA2020; available from: https://doi.org/10.1001/jama.2020.4683.

16.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.PubMedPubMedCentralCrossRef

17.

Vaduganathan M, Vardeny O, Michel T, McMurray JJ V, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; available from: https://doi.org/10.1056/NEJMsr2005760.CrossRefPubMed

18.

Pirofski L, Casadevall A. The damage–response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis. 2018;218(suppl_1):S7–11. https://doi.org/10.1093/infdis/jiy083.CrossRefPubMed

19.

Hotchkiss RS, Opal SM. Activating immunity to fight a foe - a new path. N Engl J Med. 2020;382(13):1270–2.PubMedCrossRefPubMedCentral

20.

NCI’s Surveillance and End Results program E. Age and cancer risk. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/age.

21.

Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉSL, Bhatia J, et al. Innate immunity of neonates and infants. Front Immunol. 2018;9:1759 Available from: https://pubmed.ncbi.nlm.nih.gov/30105028 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077196/.PubMedPubMedCentralCrossRef

22.

Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453–71.PubMedCrossRef

23.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451–4.PubMedPubMedCentralCrossRef

24.

Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. https://doi.org/10.1038/s41392-020-0148-4.CrossRefPubMedPubMedCentral

25.

Ménétrier-Caux C, Ray-Coquard I, Blay J-Y, Caux C. Lymphopenia in Cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 2019;7(1):85. https://doi.org/10.1186/s40425-019-0549-5.CrossRefPubMedPubMedCentral

26.

McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.PubMedCrossRef

27.

Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; Available from: https://doi.org/10.1038/s41423-020-0402-2.CrossRef

28.

Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020;2020.02.18.20024364. Available from: http://medrxiv.org/content/early/2020/02/20/2020.02.18.20024364.abstract.

29.

Zhang C, Wang X, Li S, et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun. 2019;10(1):1–11.CrossRef

30.

Wampler Muskardin TL. IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19. ACR Open Rheumatol. 2020; available from: http://www.ncbi.nlm.nih.gov/pubmed/32267072.

31.

Khamitov RA, Loginova SI, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9–13 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18756809.PubMed

32.

Alkharsah KR. VEGF upregulation in viral infections and its possible therapeutic implications. Int J Mol Sci. 2018:19(6) Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032371/.PubMedCentralCrossRef

33.

Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–61 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838146/.PubMedPubMedCentralCrossRef

34.

Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, et al. CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. Antivir Res. 2018;157:9–17.PubMedCrossRef

35.

Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3 Available from: https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/ja.PubMedCrossRef

36.

Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/.

37.

Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020; available from: https://bjgpopen.org/content/early/2020/04/07/bjgpopen20X101069.

38.

Arulanandam R, Batenchuk C, Varette O, et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun. 2015

39.

Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA - J Am Med Assoc. 2020.

40.

Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38:379–81.PubMedCrossRef

41.

Triana-Baltzer GB, Babizki M, Chan MCW, et al. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother. 2009.

42.

Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008;6:541–52.PubMedCrossRef

43.

MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. 2020;323(13):1245–6 Available from: https://jamanetwork.com/journals/jama/fullarticle/2761778.CrossRefPubMed

44.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–55 Available from: https://www.nature.com/articles/s41422-020-0305-x.PubMedPubMedCentralCrossRef

45.

Lounder DT, Bin Q, De Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019.

46.

Chen C, Huang J, Yin P, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020;2020.03.17.20037432. Available from: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v3.

47.

Blanc CA, Rosen H, Lane TE. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. J Neuroinflammation. 2014;11(1):138. https://doi.org/10.1186/s12974-014-0138-y.CrossRefPubMedPubMedCentral

48.

Sun S, Jiang Y, Wang R, Liu C, Liu X, Song N, et al. Treatment of paraquat-induced lung injury with an anti-C5a antibody: potential clinical application. Crit Care Med. 2018;46(5):e419–25 Available from: https://europepmc.org/articles/pmc5908256?pdf=render.PubMedPubMedCentralCrossRef

49.

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–50 Available from: https://www.nature.com/articles/d41573-020-00016-0.PubMedCrossRef

50.

Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020.

51.

Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. Front Immunol. 2018:8 Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2017.01981/full.

52.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92:556–63.CrossRefPubMedPubMedCentral

53.

Bian H, Zheng Z-H, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv. 2020;2020.03.21.20040691. Available from: https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.

54.

Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23(2):E71–83 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32214286.PubMed

55.

Zikuan Leng RZ, Zikuan Leng RZ. Transplantation of ACE2⁻ mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28 Available from: http://www.aginganddisease.org/EN/abstract/abstract147934.shtml.PubMedPubMedCentralCrossRef

56.

Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020; available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144273/.

57.

Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; available from: https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2763184/jamainternal_wu_2020_oi_200022.pdf.

58.

Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020; available from: https://link.springer.com/content/pdf/10.1007/s00134-020-06022-5.pdf.

59.

Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–2 Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30132-8/abstract.PubMedPubMedCentralCrossRef

60.

Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363–73. https://doi.org/10.1056/NEJMra050740.CrossRefPubMed

61.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71 Available from: https://www.nature.com/articles/s41422-020-0282-0.PubMedPubMedCentralCrossRef

62.

Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455–9 Available from: https://pdfs.semanticscholar.org/ee67/626faa30118ebe6f2ca4b4964592f25b70cd.pdf.PubMedCrossRef

63.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4 Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract.CrossRefPubMedPubMedCentral

64.

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020:1–2 Available from: https://www.nature.com/articles/s41577-020-0308-3.

65.

Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59:1088–99.PubMedPubMedCentralCrossRef

66.

Li Y, Liu X, Guo L, et al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Syst Rev. 2020;9(1):75 Available from: https://systematicreviewsjournal.biomedcentral.com/track/pdf/10.1186/s13643-020-01343-4.PubMedPubMedCentralCrossRef

67.

Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022 Available from: https://ecancer.org/en/journal/article/1022-associations-between-immune-suppressive-and-stimulating-drugs-and-novel-covid-19-a-systematic-review-of-current-evidence/pdf.PubMedPubMedCentral

68.

Chen C, Qi F, Shi K, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. 2020; available from: https://www.preprints.org/manuscript/202002.0395/v1.

69.

Rudolph AR, Tuthill CW. Treatment or prevention of respiratory viral infections with alpha thymosin peptides. 2010; available from: https://patents.google.com/patent/US20100311656A1/en.

70.

Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv. 2020;2020.02.12.945576. Available from: https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1.

71.

Muñoz M, Coveñas R, Kramer M. The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains. Acta Virol. 2019;63:253–60.PubMedCrossRef

72.

Camarri E, Amerighi A, Bellofiore P, et al. The clinical use of tranexamic acid in acute inflammation of the upper respiratory tract. G Clin Med. 1979;60(12):1010–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/540672.PubMed

73.

Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020;24(1):133 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32264963.PubMedPubMedCentralCrossRef

74.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.PubMed

75.

Blanchette PS, Chung H, Pritchard KI, et al. Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario, Canada. J Clin Oncol. 2019;37(30):2795–804. https://doi.org/10.1200/JCO.19.00354.CrossRefPubMed

76.

Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 novel coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020;105948 Available from: http://www.sciencedirect.com/science/article/pii/S0924857920300984.

77.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020.

78.

Hospital Saint-Antoine Ap-Hp - HScore. [cited 2020 Apr 13]; available from: http://saintantoine.aphp.fr/score/.

79.

Loeffelholz MJ, Tang Y-W. Laboratory diagnosis of emerging human coronavirus infections — the state of the art. Emerg Microbes Infect. 2020;9:747–56.PubMedPubMedCentralCrossRef

80.

Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. Available from: https://doi.org/10.1056/NEJMoa2007016.

81.

Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. Available from: https://doi.org/10.1056/NEJMoa2001282.PubMedCrossRef

82.

Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020;2020.03.22.20040758. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3.

83.

Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med. 2020;8(1) Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075271/.

84.

Muskardin TLW. IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19. ACR Open Rheumatol [Internet] 2020;n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/acr2.11140

85.

Bruton tyrosine kinase inhibitor. [cited 2020 Apr 14]; available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/bruton-tyrosine-kinase-inhibitor

86.

AstraZeneca. AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19. [cited 2020 Apr 14]; available from: https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html

87.

EXCLUSIVE: AstraZeneca’s Calquence shows early promise For COVID-19 patients. [cited 2020 Apr 14]; available from: https://www.forbes.com/sites/nathanvardi/2020/04/13/exclusive-astrazenecas-calquence-shows-early-promise-for-covid-19-patients/#177fd3f94677.

88.

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1 Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/abstract.PubMedPubMedCentralCrossRef

89.

Auyeung TW, Lee JSW, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51(2):98–102 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16038758.PubMedCrossRef

90.

Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197(6):700–1 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29227752.PubMedCrossRef

91.

Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.50577.

92.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90 Available from: https://academic.oup.com/jid/article-pdf/211/1/80/13805440/jiu396.pdf.PubMedCrossRef

93.

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020; available from: https://jamanetwork.com/journals/jama/fullarticle/2763983.

94.

Cheng H, Wang Y, Wang G-Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020; available from: http://www.ncbi.nlm.nih.gov/pubmed/32221983.

95.

Zhan W-Q, Li M-D, Xu M, Lu Y-B. Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report. Eur Rev Med Pharmacol Sci. 2020;24(6):3385–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32271455. PubMed

96.

Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020;8(4):e24 Available from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30119-3/abstract.PubMedPubMedCentralCrossRef

97.

Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost JTH. 2020; available from: http://www.ncbi.nlm.nih.gov/pubmed/32267998.

98.

Moore HB, Barrett CD, Moore EE, et al. Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)? J Trauma Acute Care Surg [Internet] 2020; publish Ah. Available from: https://journals.lww.com/jtrauma/Citation/publishahead/Is_There_a_Role_for_Tissue_Plasminogen_Activator.97967.aspx.

99.

Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD J Chronic Obstr Pulm Dis. 2014;11:171–6.CrossRef

100.

Chen Shi, Cong Wang, Hanxiang Wang, Chao Yang, Fei Cai, Fang Zeng, Fang Cheng, Yihui Liu, Taotao Zhou, Bin Deng, Jinping Li. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. BMJ Yale. 2020; available from: https://doi.org/10.1101/2020.03.28.20046144.

101.

Ren J-L, Zhang A-H, Wang X-J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 2020;155:104743 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32145402.PubMedPubMedCentralCrossRef

102.

赵静, 田赛赛, 杨健, 刘剑锋, 张卫东. 清肺排毒汤治疗新型冠状病毒肺炎机制的网络药理学探讨. 中草药. 2020;1–7. Available from: http://kns.cnki.net/kcms/detail/12.1108.R.20200216.2044.002.html.

103.

NCCN. Coronavirus disease 2019 (COVID-19) resources for the cancer care community. [cited 2020 Apr 9]; available from: https://www.nccn.org/covid-19/.

104.

ASCO. ASCO coronavirus resources. [cited 2020 Apr 9]; available from: https://www.asco.org/asco-coronavirus-information.

105.

ESMO. ESMO COVID-19 and cancer. [cited 2020 Apr 9]; available from: https://www.esmo.org/covid-19-and-cancer.

106.

Ontario Health Cancer Care Ontario. Pandemic planning clinical guideline for patients with cancer. [cited 2020 Apr 9]; available from: https://www.accc-cancer.org/docs/documents/cancer-program-fundamentals/oh-cco-pandemic-planning-clinical-guideline_final_2020-03-10.pdf?sfvrsn=d2f04347_2.

107.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020; available from: http://www.ncbi.nlm.nih.gov/pubmed/32243668.

108.

Cai ZX, Wen WQ, Min ZJ. Comparison of 5–FU-based and capecitabine-based neoadjuvant chemoradiotherapy in patients with rectal cancer: a meta-analysis. Clin Colorectal Cancer. 2017.

109.

Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e181.PubMedPubMedCentralCrossRef

110.

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol. 2020;189:241–3.PubMedPubMedCentralCrossRef

111.

Centers for Disease Control and Prevention. CDC: COVID-19 [cited 2020 Apr 10]; available from: https://www.cdc.gov/coronavirus/2019-nCoV/index.html.

112.

American College of Surgeons. ACS: COVID-19 and surgery. [cited 2020 Apr 10]; available from: https://www.facs.org/covid-19/clinical-guidance.

113.

Mansfield SA, Abdel-Rasoul M, Terando AM, Agnese DM. Timing of breast cancer surgery—how much does it matter? Breast J. 2017.

114.

American Society for Radiation Oncology (ASTRO). COVID-19 recommendations to radiation oncology practices. [cited 2020 Apr 10]; available from: https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information.

115.

American Society for Transplantation and Cellular Therapy (ASTCT). COVID-19 interim patient care guidelines. [cited 2020 Apr 10]; available from: https://www.astct.org/connect/astct-response-to-covid-19.

116.

Öhrmalm L, Wong M, Rotzén-Östlund M, Norbeck O, Broliden K, Tolfvenstam T. Flocked nasal swab versus nasopharyngeal aspirate for detection of respiratory tract viruses in immunocompromised adults: a matched comparative study. BMC Infect Dis. 2010;10.

117.

Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996.

118.

European Society for Blood and Marrow Transplantation (EBMT). COVID-19 and BMT. [cited 2020 Apr 10]; available from: https://www.ebmt.org/covid-19-and-bmt.

119.

FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic. The Food Drug & Administration. [cited 2020 Apr 14]; available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic.

Title: COVID-19 and Cancer: a Comprehensive Review
Authors: Rohit Gosain
Yara Abdou
Abhay Singh
Navpreet Rana
Igor Puzanov
Marc S. Ernstoff
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Coronavirus
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
Pneumonia
Acute Respiratory Distress-Syndrome
COVID-19
Published in: Current Oncology Reports / Issue 5/2020
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-020-00934-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2020

Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement

Applying the New Guidelines of HER2 Testing in Breast Cancer

The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy

Percutaneous Management of Cancer Pain

Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer

Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer